RAPP

23.1801.74%
DB

David Bredt

Founder & Chief Scientific Officer

Dr. David Bredt, M.D. PhD, serves as a Chief Scientific Officer at Rapport Therapeutics, Inc. since January 2023 and is its Founder and served as its Director since December 2022 until 2024. From February 2022 to December 2022, Dr. Bredt served as an Entrepreneur in Residence at Third Rock. From March 2021 to August 2021, Dr. Bredt served as Executive Partner at MPM Capital LLC. He identified and assessed new technologies and helped advance MPM’s company formation efforts in the field of neurology. From March 2011 to March 2021, Dr. Bredt served as Global Head of Neuroscience Discovery at Janssen Global Services, LLC. Mr. Bredt serves as a Member of Advisory Board at Switch Therapeutics Inc., since 2023. He served as Vice President of Integrated Biology at Eli Lilly & Co in August 2004 and became Vice President of Neuroscience Discovery and Early Development a few years later. He was Site Head for Johnson & Johnson’s R&D Campus in La Jolla. As head of neuroscience research at Eli Lilly, his group was responsible for Discovery through Phase 2 programs in Neurology, Psychiatry, Migraine and Pain indications. His group prosecuted numerous small and large molecules that entered preclinical and clinical development including galcanezumab / Emgality, which is now approved for preventative treatment of migraine. He was Global Head of Neuroscience Discovery at Johnson & Johnson where he had line management responsibility for neuroscience biology, biomarkers and external innovation activities. His discovery group delivered numerous small and large molecule clinical candidates for Alzheimer’s disease, major depression, schizophrenia and epilepsy. Dr. Bredt has served on the Neuroscience Forum, Institute of Medicine for National Academy of Sciences and the Advisory Panel for the National Institute of Neurological Disorders and Stroke. Dr. Bredt received a Bachelor of Arts degree in chemistry from Princeton University, a Doctor of Philosophy degree from the Johns Hopkins School of Medicine and a Doctor of Medicine degree from the Johns Hopkins School of Medicine, where he trained with Dr. Solomon H. Snyder. After graduation, he was Professor of Physiology at the University of California, San Francisco for many years. His research on nitric oxide, glutamate receptor signaling and synaptic plasticity has yielded ~225 papers, which have been cited ~75,000 times in the scientific literature. He served on the Medical Advisory Committee for the Muscular Dystrophy Association, he was an Established Investigator for the American Heart Association and he was a National Young Investigator for the National Science Foundation.

Positions